If You’re Short On Time:

  • The U.S. Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes.
  • The drug led to impressive blood sugar and body weight drops in clinical trials.
  • The approval for tirzepatide—which Lilly will market under the brand name Mounjaro—isn’t for weight loss but Type 2 diabetes.
  • Will patients, who are obese and don’t have Type 2 diabetes, ask for the drug for weight loss, and will patients understand the risks?

Every year, pharmaceutical companies contribute millions of dollars to U.S. senators and representatives as part of a multipronged effort to influence health care lawmaking and spending priorities. For example, Sen. Tim Scott, a rising star in the Republican Party with broad popularity in South Carolina, is getting showered with drug industry money before facing voters this fall.

COVID may be winding down, but the damage is done in deaths and long COVID. We don’t understand much, but we do know that there is a correlation between COVID severity and obesity/diabetes. The question thus becomes, “will the medical community finally address the obesity epidemic, or will we continue to do nothing essentially?”.